Recent immunotherapy targeting the PD1/PD-L1 (programmed cell death protein 1/PD1 ligand) immune checkpoint pathway has demonstrated durable response rates and clinical benefits11–13, indicating that tumoral immune cell infiltration and function play an important role in MCC development, growth, and clinical outcomes14–16. The gene discussed is PDCD1; the disease is Merkel cell skin cancer.